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Arsenic, a naturally occurring toxic metalloid,
is widely distributed in the environment.
Inorganic As (iAs), a chemical form of As
commonly found in drinking water supplies
(Irgolic 1994), is one of the most potent envi-
ronmental carcinogens. Worldwide, millions
of people suffer from cancer and other diseases
associated with consumption of water con-
taining high levels of iAs [Agency for Toxic
Substances and Disease Registry (ATSDR)
2007]. The conditions produced by chronic
poisoning with iAs are generally referred to as
arsenicosis. Population studies in arsenicosis-
endemic areas have consistently shown that
susceptibility to chronic toxicity of iAs varies
even among individuals at similar exposure
levels. Evidence from population, clinical,
and laboratory studies suggests that this varia-
tion is due, at least in part, to interindividual
differences in iAs metabolism. 
In humans, iAs is metabolized to methyl-
As (MAs) and dimethyl-As (DMAs) species
that contain either AsIII or AsV (Cullen et al.
1984; Devesa et al. 2004). Arsenic (+3 oxida-
tion state) methyltransferase (AS3MT) (Lin
et al. 2002) is the key enzyme in this metabolic
pathway (Drobná et al. 2006; Thomas et al.
2007). To date, four methylated arsenicals
have been identified as major metabolites of
iAs in humans: methylarsonous acid (MAsIII),
methylarsonic acid (MAsV), dimethylarsinous
acid (DMAsIII), and dimethylarsinic acid
(DMAsV). These methylated arsenicals and the
iAs species arsenate (iAsV) and arsenite (iAsIII)
are consistently detected in urine of individuals
exposed to iAs in drinking water (Aposhian
et al. 2000; Del Razo et al. 2001; Le at al.
2000; Mandal et al. 2001; Valenzuela et al.
2005). In addition, a sulfur-containing deriva-
tive of DMAsV, dimethylthioarsinic acid
(DMTA), has recently been found in urine of
residents in arsenicosis-endemic areas of
Bangladesh (Raml et al. 2007). The concentra-
tions and ratios of these As species in urine
vary significantly among individuals (Vahter
1999; Yu et al. 2000). We and others have
shown that MAsIII or DMAsIII are more potent
than iAs species or MAsV and DMAsV as cyto-
toxins, genotoxins, enzyme inhibitors, and
modulators of major signal-transduction path-
ways (Drobná et al. 2003; Mass et al. 2001;
Paul et al. 2007; Petrick et al. 2001; Styblo
et al. 2002; Thomas et al. 2001). Interrelations
in the metabolism of oxo- and thioarsenicals
have not been resolved. However, DMTA is
more toxic to mammalian cells than the penta-
valent methylated arsenicals (Naranmandura
et al. 2007). Thus, differences in the formation,
tissue retention, and clearance of AsV- and
AsIII-containing metabolites of iAs are likely to
contribute to interindividual variations in sus-
ceptibility to adverse effects associated with
iAs exposures. 
Previous studies have shown that ratios of
As species (e.g., MAs/iAs or DMAs/MAs) in
urine are associated with prevalence of skin
lesions among residents of arsenicosis-endemic
areas of Taiwan and Mexico (Chen et al. 2003;
Del Razo et al. 1997; Valenzuela et al. 2005;
Yu et al. 2000). Similar associations have been
reported between urinary levels of iAs metabo-
lites and the concentration of transforming
growth factor-α (TGF-α), a potential marker
of urinary bladder cancer, in exfoliated bladder
epithelial cells (BECs) isolated from urine of
individuals chronically exposed to iAs in drink-
ing water (Valenzuela et al. 2007). However,
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BACKGROUND: The concentration of arsenic in urine has been used as a marker of exposure to
inorganic As (iAs). Relative proportions of urinary metabolites of iAs have been identified as
potential biomarkers of susceptibility to iAs toxicity. However, the adverse effects of iAs exposure
are ultimately determined by the concentrations of iAs metabolites in target tissues. 
OBJECTIVE: In this study we examined the feasibility of analyzing As species in cells that originate
in the urinary bladder, a target organ for As-induced cancer in humans. 
METHODS: Exfoliated bladder epithelial cells (BECs) were collected from urine of 21 residents of
Zimapan, Mexico, who were exposed to iAs in drinking water. We determined concentrations of
iAs, methyl-As (MAs), and dimethyl-As (DMAs) in urine using conventional hydride generation-
cryotrapping-atomic absorption spectrometry (HG-CT-AAS). We used an optimized HG-CT-AAS
technique with detection limits of 12–17 pg As for analysis of As species in BECs. 
RESULTS: All urine samples and 20 of 21 BEC samples contained detectable concentrations of iAs,
MAs, and DMAs. Sums of concentrations of these As species in BECs ranged from 0.18 to 11.4 ng
As/mg protein and in urine from 4.8 to 1,947 ng As/mL. We found no correlations between the
concentrations or ratios of As species in BECs and in urine. 
CONCLUSION: These results suggest that urinary levels of iAs metabolites do not necessarily reﬂect
levels of these metabolites in the bladder epithelium. Thus, analysis of As species in BECs may pro-
vide a more effective tool for risk assessment of bladder cancer and other urothelial diseases associ-
ated with exposures to iAs. 
KEY WORDS: arsenic species, drinking water, exfoliated human urinary bladder epithelial cells. Environ
Health Perspect 116:1656–1660 (2008). doi:10.1289/ehp.11503 available via http://dx.doi.org/
[Online 18 July 2008]the utility of urinary As species for assessment
of health risks associated with the exposure to
iAs remains uncertain. The magnitude and
character of adverse effects of iAs exposure are
ultimately determined by the concentration
and chemical form of As in target tissues.
Therefore, analysis of total or speciated As in
these tissues could provide an effective tool for
estimating internal exposure and for identiﬁca-
tion of individuals with an increased risk of
developing specific diseases associated with
chronic exposures to iAs. 
Development of sensitive techniques for
analysis of trivalent and pentavalent As species
in complex biological matrices, including
human cells and tissues, is a prime require-
ment for better understanding of dose–
response relations for iAs in humans. We have
recently optimized instrumentation and
methods for speciation analysis of As by
hydride generation-atomic absorption spec-
trometry using a cryotrap (HG-CT-AAS) for
capture and separation of arsines, and a multi-
ple microflame quartz tube atomizer (multi-
atomizer) for a more efﬁcient atomization of
As (Matous ˘ek et al. 2002, 2008). We used the
optimized HG-CT-AAS in the present study
for analysis of As species in BECs isolated
from individuals chronically exposed to iAs in
drinking water. Our results show that both
urine and BECs contain iAs and its methy-
lated metabolites MAs and DMAs. However,
we found no correlations between the concen-
trations or ratios of As species in urine and
BECs. These ﬁndings suggest that speciation
of As in BECs rather than in urine should be
used for risk assessment of diseases affecting
urinary bladder or urothelium of individuals
chronically exposed to iAs. 
Materials and Methods
Study subjects. Twenty-one individuals
(19 females and 2 males; 14–64 years of age)
were randomly selected from 196 subjects
involved in an ongoing population study in
Zimapan, Mexico. Concentrations of iAs in
drinking water from wells used by these sub-
jects ranged from < 1 to 190 µg As/L. The pro-
tocol for this study was approved by the
Human Research Ethics Boards of the
University of North Carolina (UNC) at Chapel
Hill and of Centro de Investigación y de
Estudios Avanzados del Instituto Politécnico
Nacional (CINVESTAV), Mexico. All partici-
pants gave written informed consent.
Collection of urine and isolation of BECs.
Spot urine samples were collected in acid-
washed polypropylene containers in local health
department facilities in Zimapan. The contain-
ers were packed in ice and transported to CIN-
VESTAV laboratories, which are located in
Mexico City, about a 2-hr drive from Zimapan.
Here, each urine sample was divided into two
or three 50-mL polyethylene tubes. BECs were
isolated by centrifugation at 300 × g for 10 min
at 4°C. Cells from each donor were then trans-
ferred into a single conical 1.5-mL Eppendorf
tube, washed with ice-cold phosphate-buffered
saline (PBS), and centrifuged at 300 ×g for
5 min at 4°C. Cells were washed again with
PBS and pelleted by centrifugation. The pellets
were packed in dry ice and air-shipped to
UNC-Chapel Hill. Here, the pellets were
stored for several days at –80°C before analysis.
Aliquots of urine were stored at –75°C until
analyzed at CINVESTAV.
Analysis of As species in urine and BECs.
We analyzed arsenic species in urine by HG-
CT-AAS using a PerkinElmer Model 3100
AA spectrometer (PerkinElmer, Norwalk, CT,
USA) equipped with a conventional quartz
tube atomizer (Del Razo et al. 2001).
Hydrides (i.e., arsine and the methyl-substi-
tuted arsines) were generated in a reaction
with sodium borohydride (NaBH4; EM
Science, Gibbstown, NJ, USA) in the presence
of concentrated HCl (Sigma-Aldrich, St.
Louis, MO, USA). Under these conditions,
hydrides are generated from both trivalent and
pentavalent As species (Del Razo et al. 2001;
Devesa et al. 2004). We analyzed As species in
BECs by a recently developed automated HG-
CT-AAS technique using a PerkinElmer
Model 5100 PC AA spectrometer equipped
with the multiatomizer and a FIAS200 flow
injection accessory (Hernández-Zavala et al.
2008; Matous ˘ek et al. 2008). Unlike the con-
ventional HG-AAS used for the urine analy-
ses, the new method provides low detection
limits (DLs) needed for analysis of As species
in small samples of BECs. Before analysis,
each BEC pellet was lysed in 1.25 mL 0.5%
solution of Triton X-100 (Sigma-Aldrich) in
deionized water. BEC lysates were treated with
2% L-cysteine hydrochloride (EMD Chemicals
Inc., Darmstadt, Germany) for 70 min at
room temperature. Treatment with cysteine
reduces all pentavalent As species to trivalency.
Hydrides were generated from 0.5-mL
aliquots of cysteine-treated samples by reac-
tion with NaBH4 in a Tris-HCl (Sigma-
Aldrich) buffer (pH 6) as previously described
(Hernández-Zavala et al. 2008; Matous ˘ek
et al. 2008). HG-CT-AAS was developed for
the oxidation-state–speciﬁc speciation analysis
of As, but under current operating conditions
both procedures described above determined
total iAs (iAsIII + iAsV), MAs (MAsIII +
MAsV), and DMAs (DMAsIII + DMAsV). 
Calibration and method validation. We
used the following standards to generate cali-
bration curves for quantiﬁcation of iAs, MAs,
and DMAs: iAsV, sodium salt, (96% pure;
Sigma-Aldrich), MAsV, disodium salt (98%
pure; Chem Service, West Chester, PA, USA),
and DMAsV (98% pure; Strem Chemicals,
Inc., Newburyport, MA, USA). Standard
solutions for quantification of As species in
urine were prepared in deionized water. For
quantiﬁcation of As species in BECs, the stan-
dards solutions were spiked into Triton X-100
lysates of human hepatocellular carcinoma
(HepG2) cells (American Type Culture
Collection, Manassas, VA, USA). Identities of
arsines generated from urine and BECs were
confirmed by spiking samples with As
standards at several concentrations. 
Concentrations of iAs, MAs, and DMAs
were expressed as nanograms As per milliliter
for urine and nanograms As per milligram pro-
tein for BECs. The protein concentrations in
BEC lysates were determined using an RC DC
Protein Assay kit (BioRad, Hercules, CA,
USA); bovine serum albumin was used for assay
calibration. We used standard reference mater-
ial (SRM) 2670a urine (National Institute of
Standards and Technology, Gaithersburg, MD,
USA), with a reference value for total As con-
centration of 220 µg/L, for validation of urine
analyses. The sum of As species (mean ± SD;
n = 3) determined in SRM 2670a urine by con-
ventional HG-CT-AAS (207 ± 6 µg As) was in
good agreement with the reference value for
total As content. There are no SRMs for analy-
sis of total As or As species in cells or tissues.
However, our previous studies showed that the
recoveries of As species from human cell lysates
pretreated with cysteine and analyzed by the
automated HG-CT-AAS with the multiat-
omizer range from 88 to 98% (Hernández-
Zavala et al. 2008).
Statistical analyses. We used Stata 8.0
(Stata Corp., College Station, TX, USA) and
Instat (GraphPad Software Inc., San Diego,
CA, USA) statistical software packages to ana-
lyze results of this study. Differences in the
percentages of As species and the species ratios
between urine and BECs were evaluated by
unpaired t-test. The nonparametric Spearman
correlation was used to analyze associations
between the concentrations of As species,
the percentage of As species, or ratios of As
species in urine and BECs. Differences or cor-
relation with p-values < 0.05 were considered
statistically signiﬁcant. 
Results and Discussion 
BECs exfoliated into urine originate in epithe-
lium of the genitourinary tract including the
urinary bladder. The basic characteristics of
blood and urine (e.g., chemical composition,
pH, osmolality) differ signiﬁcantly. The apical
surface of the bladder epithelium represents an
effective permeability barrier that maintains
large chemical and electrical gradients between
the urine and the blood (Hicks et al. 1974). In
humans, turnover of superficial BECs takes
about 200 days (Born et al. 2003). Thus,
BECs isolated by catheterization and washing
of the bladder epithelium or BECs collected
from voided urine are a unique material for
study of metabolic or genetic changes in
Arsenic species in exfoliated bladder cells
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long-term exposures to toxins or carcinogens.
Notably, BECs exfoliated to the urine are
viable and can be cultured (Dörrenhaus et al.
2000; Herz et al. 1993). Diagnostic tests on
exfoliated BECs (e.g., analyses of tumor anti-
gens, nuclear matrix proteins, ﬁbrin degrada-
tion products, telomerase activity) have the
potential to replace cystoscopies or resections
in the diagnosis of bladder tumors (Ozen
1999). BECs have also been used to measure
cytogenetic end points in studies evaluating
genotoxic effects of chemical carcinogens tar-
geting urinary bladder, including iAs (Murray
and Edwards 1999; Warner et al. 1994). An
exposure-dependent increase in micro-
nucleated BECs was reported among individu-
als exposed to iAs in drinking water (Biggs
et al. 1997; Moore et al. 1997). However,
because of limitations of methods used for
analysis of As species in biological samples,
association between the micronucleus forma-
tion or other pathologic processes and the
concentrations of iAs metabolites in BECs has
not been examined.
HG-CT-AAS is uniquely suited for quan-
titative analysis of As species in complex bio-
logical matrices in which arsenicals are bound
to protein or low-molecular-weight thiols.
Some of these matrices, specifically cell
lysates, can be analyzed directly without prior
digestion or extraction, thus limiting oxida-
tion of the unstable methylated AsIII-contain-
ing species. We have recently optimized this
technique, increasing its sensitivity consider-
ably for all relevant As species and improving
its throughput (Hernández-Zavala et al.
2008; Matous ˘ek et al. 2008). The optimized
HG-CT-AAS was used in the present study
for speciation analysis of As in BECs collected
from individuals chronically exposed to iAs in
drinking water. To match the matrix of BEC
cells, As standards used for calibration were
prepared in HepG2 lysates at ﬁnal concentra-
tions of 0.1–5 ng As/mL. The calibration
curves for iAsV, MAsV, and DMAsV standards
were linear over the entire concentration
range (Table 1); the DL values were 12 pg As
for iAsV, 17 pg As for MAsV, and 13 pg As
for DMAsV. Precision of the method
expressed as relative SD for three As standard
concentrations (0.25, 0.5, and 1 ng) ranged
from 0.7 to 3.1% (data not shown). Figure 1
shows examples of AAS signals for arsine,
methylarsine, and dimethylarsine generated
from a mixture of As standards (iAsV, MAsV,
and DMAsV) prepared in HepG2 lysates and
from BEC samples (donors 15 and 18) pre-
treated with cysteine. In both cases, complete
baseline separations of arsine, methylarsine,
and dimethylarsine were achieved. The aver-
age retention times (mean ± SD) were 7.8 ±
0.11 sec for arsine, 30 ± 0.38 sec for methy-
larsine, and 39.3 ± 0.4 sec for dimethylarsine. 
Table 2 and Figure 2 summarize the speci-
ation analysis of As in BECs and urine. iAs,
MAs, and DMAs were present in all 21 urine
samples. The sum of As species in urine
ranged from 4.8 to 1,947 ng As/mL. DMAs
was the major As species, accounting for an
average of 69% of iAs metabolites in urine.
iAs, MAs, and DMAs were also detected in
20 of 21 BEC samples. The levels of As
species in BECs from donor 1 were < DLs of
the method. The sum of As species in BECs
ranged from 0.18 to 11.4 ng As/mg protein.
On average, iAs represented a significantly
greater fraction of As species in BECs (42%)
compared with urine (17%). On average,
DMAs accounted for about 43% of As species
in BECs. MAs was a minor metabolite in both
BECs and urine, accounting for an average of
15% and 13%, respectively. Consequently,
the MAs/iAs, DMAs/MAs, and DMAs/iAs
ratios were signiﬁcantly greater in urine than
in BECs. The ratios of As metabolites in
human urine have frequently been interpreted
as indicators of the efﬁciency of iAs methyla-
tion or as markers of the individual capacity to
methylate iAs. However, the actual associa-
tions between the As metabolites excreted in
urine and those retained in tissues have never
been properly examined. In this study, no sta-
tistically significant correlations were found
between the sum of As species in urine and
BECs or between the concentrations of the
individual As species or the ratios of As species
in urine and BECs. Similarly, no statistically
significant correlations were found between
the age of study subjects and the concentra-
tions, percentages, or ratios of As species in
urine or BECs.
Our results show that the levels and com-
position of iAs metabolites in BECs do not
reflect those found in urine. Several factors
could affect the concentrations and speciation
Hernández-Zavala et al.
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Table 1. The characteristics of the calibration curves and DLs for As species analyzed by the optimized
HG-CT-AAS.
As standards Linear regressiona Correlation coefﬁcienta DL (pg As)b
iAsV y = 1.04x + 0.041 0.999 12
MAsV y = 0.94x + 0.02 0.999 17
DMAsV y = 1.03x + 0.046 0.999 13
aCalibration curves were generated for As standards spiked into a HepG2 cell lysate at ﬁnal concentrations of 0.1–5 ng
As/mL; all standards were treated with cysteine before HG-CT-AAS analysis. bDLs were calculated as 3 sigma for the
area of blanks (n = 10) at retention times corresponding to each of the As species. 
Figure 1. HG-CT-AAS analysis of As standards and As species in BECs showing separation and detection of
arsine (a), methylarsine (b), and dimethylarsine (c) generated from a mixture of As standards, iAsV, MAsV,
and DMAsV (0.5 ng As each), spiked into a HepG2 cell lysate (A) and from BECs isolated from two subjects
included in this study (B). The mixture of standards and BEC lysates were treated with cysteine to allow
arsine generation from both trivalent and pentavalent As species. 
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aof As in BECs after separation from bladder
epithelium, including a) the integrity of the
plasma membrane, b) the activity of cellular
transport systems regulating the influx and
efﬂux of As species in BECs, c) the capacity of
BECs to methylate iAs, and d) the binding of
As species to high-affinity targets in BECs.
Previous work showed that BECs collected at
the same study site in Zimapan and processed
using the same protocol maintained morpho-
logic integrity (Valenzuela et al. 2007). This
observation is consistent with results of clini-
cal studies (Dörrenhaus et al. 2000; Herz
et al. 1993) in which BECs were used to
examine potential biomarkers of bladder can-
cer. We have previously shown that SV-40–
transformed normal human urinary bladder
epithelial (UROtsa) cells do not express
AS3MT and do not methylate iAs (Drobná
et al. 2005). AS3MT expression and activity
in BECs have not yet been examined.
Cultured UROtsa cells exposed to equimolar
concentrations of iAsIII, MAsIII, or DMAsIII
retained MAsIII and DMAsIII more avidly
than iAsIII (Drobná et al. 2005), indicating
that uptake or binding processes in these cells
favor methylated trivalent arsenicals.
However, in the present study, iAs repre-
sented a major fraction of As species retained
in BECs but was only a minor As species in
urine. These data suggest that the afﬁnity of
BECs for iAs and methylated As species may
differ from that of cultured UROtsa cells.
The multidrug resistance-associated protein-1
and -2 and P-glycoprotein, which mediate
transport of arsenicals in cell culture systems
(Kala et al. 2000; Liu et al. 2001, 2006; Steele
et al. 2005), are expressed in UROtsa cells
(Drobná et al., unpublished data). Future
studies will examine the expression and activi-
ties of these transporters in BECs and the
roles of these transporters in accumulation of
speciﬁc As species in these cells. 
Conclusions
The results of this study conﬁrm that the opti-
mized HG-CT-AAS is suitable for speciation
analysis of As in small samples of exfoliated
BECs. Notably, these results also suggest that
the concentration and speciation of As in
BECs do not correlate with the concentration
and speciation of As in urine. The urinary pro-
ﬁles of As species have been shown to reﬂect
only a recent exposure to iAs; however, the
concentrations of As species in BECs are likely
to reﬂect the integrated exposure over a period
of about 200 days, the lifetime of the superﬁ-
cial layer of bladder epithelium (Born et al.
2003). Thus, analysis of As species in BECs
may provide a more effective tool for risk
assessment of bladder cancer and, possibly,
other diseases associated with chronic exposure
to iAs. The optimized HG-CT-AAS will be
used in our future studies for the oxidation
state specific analysis of As species in BECs
with focus on the most toxic metabolites of
iAs: MAsIII and DMAsIII. In addition, we
plan to examine association between the con-
centrations of As species in BECs and markers
of the adverse effects of iAs exposure, includ-
ing micronucleus formation and TGF-α
concentration in BECs and skin lesions.
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